Sumary of Hope of alternative treatment for osimertinib-relapsed lung cancer patients:
- Additional targeted options Byoung Chul Cho, M.D., Ph.D., Yonsei Cancer Center, Yonsei University College of Medicine in Seoul, South Korea, and lead study investigator, said:.
- “Typically, patients whose disease no longer responds to osimertinib therapy would have little opportunity to seek additional treatments, other than chemotherapy..
- However, the durable responses we are seeing with the combination of amivantamab and lazertinib suggest an additional targeted option may be possible..
- The most common adverse events were predominantly Grade 1-2 and included infusion-related reactions (78%), rash (acneiform dermatitis, 51% + rash, 27%) and paronychia (49%)….